ROIV vs. UTHR: Roivant Sciences vs. United Therapeutics Stock Comparison
How do Roivant Sciences (ROIV) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Roivant Sciences (ROIV) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
United Therapeutics (UTHR) has more than two decades of public-market history since June 17, 1999, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.
| Profile Item | ROIV | UTHR |
|---|---|---|
| Name | Roivant Sciences Ltd. | United Therapeutics Corporation |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 28.08 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | December 8, 2020 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Total Return (1Y) | 96.75% | 28.77% |
| Total Return (3Y, Annualized) | 68.04% | 37.63% |
| Total Return (5Y, Annualized) | 36.73% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 47.99% | 35.00% |
| Beta (5Y) | 1.17 | 0.49 |
| Max Drawdown (5Y) | -79.22% | -33.00% |
| Avg. Volume (3M) | 7.82M | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 1.93 | 0.70 |
| Sortino Ratio (1Y) | 4.03 | 1.29 |
Profitability
ROE (TTM)
Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile United Therapeutics (UTHR) reports 28.99%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| ROE (TTM) | -8.52% | 19.13% |
| ROA (TTM) | -16.28% | 10.91% |
| Net Margin (TTM) | 0.00% | 38.61% |
| Operating Margin (TTM) | -25,408.11% | 28.99% |
| Gross Margin (TTM) | 0.00% | 86.34% |
Growth
Revenue Growth
United Therapeutics (UTHR) at 10.61% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.
Growth Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Revenue Growth (YoY) | -71.57% | 10.61% |
| Revenue Growth (3Y CAGR) | -36.01% | 18.02% |
| EPS Growth (YoY) | -- | 13.07% |
| EPS Growth (3Y CAGR) | -- | 22.92% |
Financial Strength
Current Ratio (MRQ)
United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Roivant Sciences (ROIV) carries debt-to-equity ratio of 0.02 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 16.72 | 4.61 |
| Debt / Equity (MRQ) | 0.02 | -- |
| Net Debt / EBITDA | -- | -1.53 |
Dividends
Dividend Yield (TTM)
Neither Roivant Sciences (ROIV) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Roivant Sciences (ROIV) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
United Therapeutics (UTHR) at 7.51 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
United Therapeutics (UTHR) at 3.80 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ROIV | UTHR |
|---|---|---|
| P/E Ratio (TTM) | -- | 21.22 |
| P/S Ratio (TTM) | 3,728.61 | 7.51 |
| P/B Ratio (MRQ) | 6.64 | 3.80 |
| Free Cash Flow Yield (TTM) | -3.98% | 1.90% |